التفاصيل البيبلوغرافية
| العنوان: |
SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022) |
| المؤلفون: |
García-Campelo, Rosario, Sullivan, Ivana, Arriola, Edurne, Insa, Amelia, Juan Vidal, Oscar, Cruz-Castellanos, Patricia, Morán, Teresa, Reguart, Noemí, Zugazagoitia, Jon, Dómine, Manuel |
| المصدر: |
Clinical and Translational Oncology ; volume 25, issue 9, page 2679-2691 ; ISSN 1699-3055 |
| بيانات النشر: |
Springer Science and Business Media LLC |
| سنة النشر: |
2023 |
| مصطلحات موضوعية: |
Cancer Research, Oncology, General Medicine |
| الوصف: |
Small-cell lung cancer (SCLC) is a highly aggressive malignancy comprising approximately 15% of lung cancers. Only one-third of patients are diagnosed at limited-stage (LS). Surgical resection can be curative in early stages, followed by platinum–etoposide adjuvant therapy, although only a minority of patients with SCLC qualify for surgery. Concurrent chemo-radiotherapy is the standard of care for LS-SCLC that is not surgically resectable, followed by prophylactic cranial irradiation (PCI) for patients without progression. For extensive-stage (ES)-SCLC, a combination of platinum and etoposide has historically been a mainstay of treatment. Recently, the efficacy of programmed death-ligand 1 inhibitors combined with chemotherapy has become the new front-line standard of care for ES-SCLC. Emerging knowledge regarding SCLC biology, including genomic characterization and molecular subtyping, and new treatment approaches will potentially lead to advances in SCLC patient care. |
| نوع الوثيقة: |
article in journal/newspaper |
| اللغة: |
English |
| DOI: |
10.1007/s12094-023-03216-3 |
| DOI: |
10.1007/s12094-023-03216-3.pdf |
| DOI: |
10.1007/s12094-023-03216-3/fulltext.html |
| الإتاحة: |
https://doi.org/10.1007/s12094-023-03216-3Test |
| حقوق: |
https://creativecommons.org/licenses/by/4.0Test ; https://creativecommons.org/licenses/by/4.0Test |
| رقم الانضمام: |
edsbas.EC251E95 |
| قاعدة البيانات: |
BASE |
